Aspects of Blood Pressure, Lipid, and Glycemic Treatment

Diabetes Care

Volumn 27, Issue 1, 2004, Pages 264-269

  Bloomgarden, Zachary T ^a,b  

^a Mount Sinai School of Medicine ^*

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ANTIBIOTIC AGENT; ANTILIPEMIC AGENT; CHLORTALIDONE; EZETIMIBE; FATTY ACID; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; GLUCOSE; GLUCOSE TRANSPORTER 4; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; OMEGA 3 FATTY ACID; PRAVASTATIN; ROSUVASTATIN; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN C; SULFONYLUREA DERIVATIVE; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG SAFETY; DYSLIPIDEMIA; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MORTALITY; MOUSE; MULTIPLE ORGAN FAILURE; MYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEPSIS; STRESS; TREATMENT OUTCOME;

BLOOD PRESSURE; CRITICAL ILLNESS; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LIPID METABOLISM;

EID: 1042280187     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.1.264     Document Type: Review

References (25)

1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial: major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 288:2981-2997, 2002
2. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
3. 1c as markers of diabetic complications: Diabetes Control and Complications Trial. Diabetes 48:870-880, 1999
4. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE: Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Endocrinol Metab 87:978-982, 2002
5. Kitabchi AE: Low-dose insulin therapy in diabetic ketoacidosis: factor fiction? Diabete Metab Rev 5:337-363, 1989
6. Mesotten D, Delhanty PJ, Vanderhoydonc F, Hardman KV, Weekers F, Baxter RC, Van Den Berghe G: Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. J Endocrinol Metab 87:5516-5523, 2002
7. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in the critically ill patients. N Engl J Med 345:1359-1367, 2001
8. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G: Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Endocrinol Metab 88:1082-1088, 2003
9. Gwilt DJ, Nattrass M, Pentecost BL: Use of low-dose insulin infusions in diabetics after myocardial infarction. Br Med J (Clin Res Ed) 285:1402-1404, 1982
10. Gwilt DJ, Petri M, Lamb P, Nattrass M, Pentecost BL: Effect of intravenous insulin infusion on mortality among diabetic patients after myocardial infarction. Br Heart J 51:626-630, 1984
11. Clark RS, English M, McNeill GP, Newton RW: Effect of intravenous infusion of insulin in diabetics with acute myocardial infarction. Br Med J (Clin Res Ed) 291:303-305, 1985
12. Davies RR, Newton RW, McNeill GP, Fisher BM, Kesson CM, Pearson D: Metabolic control in diabetic subjects following myocardial infarction: difficulties in improving blood glucose levels by intravenous insulin infusion. Scott Med J 36:74-76, 1991
13. Malmberg KA, Efendic S, Ryden LE: Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction: a report from the multicenter trial: DIGAMI. Diabetes Care 17:1007-1014, 1994
14. Malmberg K, the DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ 314:1512-1515, 1997
15. Melidonis A, Stefanidis A, Tournis S, Manoussakis S, Handanis S, Zairis M, Dadiotis L, Foussas S: The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients. Clin Cardiol 23:160-164, 2000
16. Holdaas H, Fellstrom B, Jardine AG, Holme I, Nyberg G, Fauchald P, Gronhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambuhl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR, the Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators: Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 361:2024-2031, 2003
17. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS: Regression of microalbuminuria in type 1 diabetes. N Engl J Med 348:2285-2293, 2003
18. Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W: Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 8:1245-1255, 1986
19. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, Dowdy AA, Marino EK, Bolson EL, Alaupovic P, Frohlich J, Albers JJ: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583-1592, 2001
20. Gotto AM Jr, Whitney E, Stein EA, Shapiro DR, Clearfield M, Weis S, Jou JY, Langendorfer A, Beere PA, Watson DJ, Downs JR, de Cani JS: Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101:477-484, 2000
21. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, Gotto AM Jr: Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 99:736-743, 1999
22. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J: Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 104:3046-3051, 2001
23. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, the VA-HIT Study Group: Veterans Affairs High-Density Lipoprotein Intervention Trial: relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285:1585-1591, 2001.
24. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Manttari M, Heinonen OP, Frick MH: Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 85:37-45, 1992
25. The Diabetes Atherosclerosis Intervention Study Group: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910, 2001